Paxlovid Rebound in COVID-19: Where We Stand on Drug Regimens
This site is intended for healthcare professionals

COMMENTARY

Paxlovid Rebound in COVID-19: Where We Stand on Drug Regimens

Robert D. Glatter, MD; Paul G. Auwaerter, MD

Disclosures

September 01, 2022

0

This discussion was recorded on August 18, 2022. This transcript has been edited for clarity.

Robert D. Glatter, MD: Welcome. I'm Dr Robert Glatter, medical advisor for Medscape Emergency Medicine. Today, we'll be discussing the topic of Paxlovid rebound, which has been front and center in the news. Both Dr Fauci and President Biden experienced the phenomenon.

Joining us to discuss the topic is Dr Paul Auwaerter, professor of medicine and clinical director, Division of Infectious Diseases at Johns Hopkins University School of Medicine.

Welcome, Paul.

Paul G. Auwaerter, MD: I'm glad to be here. This is a topic many patients and physicians have questions about.

Glatter: Absolutely. I want to start off by defining for the audience what Paxlovid rebound is and how you would explain that.

Auwaerter: Right. I would divide it into two possible areas. One would be that people improve and then have some symptoms of recurrence, whether it's upper respiratory, lower respiratory, or perhaps fever. Does the syndrome recur?

The other would be, for those who especially have at-home antigen tests in hand, where we know that measures about 105or higher logs of the virus, does your test become negative and turn positive? Or does your test still stay positive (for those who haven't checked after taking a course of Paxlovid), usually 2-3 days after you stop, for up to a week later?

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....